Security key
92941V308
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 (VYNE)
CUSIP: 92941V308
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 33,333,333
- Total 13F shares
- 7,312,555
- Share change
- -652,219
- Total reported value
- $14,256,902
- Price per share
- $1.88
- Number of holders
- 31
- Value change
- -$1,226,342
- Number of buys
- 5
- Number of sells
- 12
Report period
Q3 2024
Institutions
31
Top holders
10
VYNE full security history
Newer quarter: Q4 2024
Previous quarter: Q2 2024
VYNE Therapeutics Inc. SEC filings
VYNE Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92941V308
Recent filing periods:
Top shareholders of VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
4.2%
|
1,394,336
|
$3,130,284 | — | 30 Jun 2024 | |
| Cormorant Asset Management, LP |
13F
|
Company |
4.2%
|
1,394,336
|
$2,746,842 | — | 30 Jun 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.6%
|
1,211,066
|
$2,385,800 | — | 30 Jun 2024 | |
| DSC Advisors, L.P. |
13F
|
Company |
2.1%
|
696,465
|
$1,372,036 | — | 30 Jun 2024 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
467,397
|
$920,772 | — | 30 Jun 2024 | |
| Palo Alto Investors LP |
13F
|
Company |
1.3%
|
445,434
|
$877,505 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.3%
|
443,518
|
$873,731 | — | 30 Jun 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
1.1%
|
353,434
|
$696,265 | — | 30 Jun 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1%
|
345,206
|
$680,056 | — | 30 Jun 2024 | |
| AlphaCentric Advisors LLC |
13F
|
Company |
0.93%
|
310,500
|
$611,685 | — | 30 Jun 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.65%
|
216,223
|
$425,959 | — | 30 Jun 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.51%
|
171,217
|
$337,297 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.41%
|
135,670
|
$267,285 | — | 30 Jun 2024 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.2%
|
65,034
|
$128,117 | — | 30 Jun 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.19%
|
63,111
|
$124,329 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.18%
|
60,581
|
$119,345 | — | 30 Jun 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.18%
|
60,323
|
$118,836 | — | 30 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.11%
|
37,655
|
$74,180 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0.08%
|
25,058
|
$49,365 | — | 30 Jun 2024 | |
| Lynx1 Capital Management LP |
13F
|
Company |
0.05%
|
16,194
|
$31,902 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.05%
|
15,765
|
$31,057 | — | 30 Jun 2024 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.01%
|
4,456
|
$9,000 | — | 30 Jun 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
3,383
|
$6,665 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
2,306
|
$4,542 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
1,799
|
$3,544 | — | 30 Jun 2024 | |
| MB, LEVIS & ASSOCIATES, LLC |
13F
|
Company |
0%
|
1,041
|
$2,051 | — | 30 Jun 2024 | |
| Centerpoint Advisors, LLC |
13F
|
Company |
0%
|
350
|
$1,000 | — | 30 Jun 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0%
|
187
|
$368 | — | 30 Jun 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
176
|
$347 | — | 30 Jun 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
65
|
$128 | — | 30 Jun 2024 | |
| PERCEPTIVE ADVISORS LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,935,057
|
$11,251,930 | — | 16 Aug 2021 | |
| AI Biotechnology LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,116,585
|
$2,545,814 | — | 01 Nov 2023 | |
| Andrew Saik |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
116,468
|
$265,547 | — | 28 May 2021 | |
| Matthew T. Wiley |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
109,246
|
$249,081 | — | 30 Jun 2021 | |
| STALEY CAPITAL ADVISERS INC |
13F
|
Company |
—
class O/S missing
|
36,472
|
$71,850 | — | 30 Jun 2024 | |
| Ashton Thomas Private Wealth, LLC |
13F
|
Company |
—
class O/S missing
|
19
|
$37 | — | 30 Jun 2024 | |
| Rex Bright |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 19 Jul 2021 |
Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 (VYNE) as of Q3 2024
As of 30 Sep 2024,
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 (VYNE) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,312,555 shares.
The largest 10 holders included
EVENTIDE ASSET MANAGEMENT, LLC, Cormorant Asset Management, LP, CITADEL ADVISORS LLC, DSC Advisors, L.P., Palo Alto Investors LP, VANGUARD GROUP INC, Exome Asset Management LLC, AlphaCentric Advisors LLC, Parkman Healthcare Partners LLC, and Schonfeld Strategic Advisors LLC.
This page lists
32
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
30
Q3 2024 holders
31
Holder diff
1
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.